BOSTON SCIENTIFIC CORP
BOSTON SCIENTIFIC CORP (BSX) Stock News
The latest BSX headlines and market coverage — 4 recent stories, updated throughout the day.
- Zacks Investment Research·
Why Boston Scientific (BSX) Outpaced the Stock Market Today
Boston Scientific (BSX) closed at $42.73, up 1.64% on the day, outperforming the S&P 500. The company is expected to report earnings on October 28, 2026, with predicted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY). However, BSX holds a Zacks Rank #4 (Sell) rating due to a 1.3% decline in consensus EPS estimates over the past month. The stock trades at a Forward P/E of 12.92, below its industry average, but faces headwinds despite valuation appeal.
- Zacks Investment Research·
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific (BSX) gained 1.11% on October 8, 2026, outperforming the broader market decline. The medical device manufacturer is expected to report Q3 earnings on October 28 with forecasted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY). However, the stock has declined 7.52% over the past month and holds a Zacks Rank of #4 (Sell) following a 1.3% decrease in consensus EPS estimates over the last 30 days. The stock trades at a Forward P/E of 12.78, below its industry average of 19.24.
- Zacks Investment Research·
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
Boston Scientific (BSX) declined 1.46% to $42.60, underperforming the broader market which gained 0.73%. The stock has lost 7.92% over the past month. While analysts expect modest earnings growth of 1.33% YoY and revenue growth of 3.25% for the upcoming quarter, the company received a Zacks Rank #4 (Sell) rating due to a 1.3% downward revision in consensus EPS estimates over the last 30 days. However, the stock trades at a discount with a Forward P/E of 13.28 versus the industry average of 19.67.
- Zacks Investment Research·
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
While Wall Street analysts maintain an optimistic average brokerage recommendation (ABR) of 1.53 (Strong Buy/Buy equivalent) for Boston Scientific with 21 Strong Buy ratings out of 30 recommendations, the article cautions investors to look beyond analyst sentiment. The Zacks Rank system assigns BSX a #5 (Strong Sell) rating due to a 0.3% decline in consensus earnings estimates over the past month to $3.29, suggesting analysts' growing pessimism about the company's earnings prospects. The article emphasizes that brokerage recommendations often have positive bias due to vested interests, while earnings estimate revisions are a more reliable predictor of near-term stock price movements.